PMID- 25778460
OWN - NLM
STAT- MEDLINE
DCOM- 20160224
LR  - 20220331
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 5
DP  - 2015 Mar 16
TI  - N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of 
      risperidone treatment in first-episode drug-naive schizophrenia patients.
PG  - 9109
LID - 10.1038/srep09109 [doi]
LID - 9109
AB  - It is unclear whether N-acetylaspartate (NAA) depletions documented in 
      schizophrenia patients might be due to the disease progression or medications. 
      Here we investigated longitudinal NAA changes in drug-naive first-episode 
      patients (FEP) who are relatively free from chronicity. Forty-two drug-naive FEP 
      and 38 controls were enrolled in this study to explore the effect of 8-week 
      risperidone monotherapy on NAA. All spectra were obtained from the medial 
      prefrontal cortex (MPFC) on a 3.0 T MRI and analyzed with LCModel. At baseline, 
      patients presented no significant differences in NAA (P = 0.084) or NAA/Cr + Pcr 
      (P = 0.500) compared to controls; NAA levels were negatively correlated with 
      PANSS total scores (P = 0.001) and WCST-PE (P = 0.041). After treatment, patients 
      demonstrated significant reductions of NAA (P < 0.001) and NAA/Cr + Pcr (P < 
      0.001), and significant improvement in PANSS-P (P < 0.001) and PANSS-G (P < 
      0.001) symptoms. We detected no significant correlations between NAA alterations 
      and PANSS-P (P = 0.679) or PANSS-G (P = 0.668) symptom changes; nor did NAA/Cr + 
      Pcr changes with alterations in PANSS-P (P = 0.677) and PANSS-G (P = 0.616). This 
      is the first evidence that short-term risperidone treatment induces an acute 
      reduction of MPFC NAA during the early phase of schizophrenia, which may be a 
      previously unavailable biomarker to indicate risperidone with a similar 
      pharmacological mechanism, although the functional significance is still unclear.
FAU - Zong, Xiaofen
AU  - Zong X
AD  - Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Hu, Maolin
AU  - Hu M
AD  - Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Li, Zongchang
AU  - Li Z
AD  - Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Cao, Hongbao
AU  - Cao H
AD  - Unit on Statistical Genomics, National Institute of Mental Health, NIH, Bethesda, 
      USA.
FAU - He, Ying
AU  - He Y
AD  - Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Liao, Yanhui
AU  - Liao Y
AD  - Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Sang, Deen
AU  - Sang D
AD  - Department of Radiology, The Second Affiliated Hospital of Xinxiang Medical 
      University, Xinxiang, Henan, China.
FAU - Zhao, Hongzeng
AU  - Zhao H
AD  - Department of Radiology, The Second Affiliated Hospital of Xinxiang Medical 
      University, Xinxiang, Henan, China.
FAU - Tang, Jinsong
AU  - Tang J
AD  - Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Lv, Luxian
AU  - Lv L
AD  - Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, 
      Henan, PR China; Department of Psychiatry, The Second Affiliated Hospital of 
      Xinxiang Medical University, Xinxiang, Henan, China.
FAU - Chen, Xiaogang
AU  - Chen X
AD  - 1] Institute of Mental Health, the Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China [2] Key Laboratory of Psychiatry and Mental 
      Health of Hunan Province, Central South University, Changsha, Hunan, China [3] 
      National Technology of Institute of Psychiatry, Central South University, 
      Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150316
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antipsychotic Agents)
RN  - 30KYC7MIAI (Aspartic Acid)
RN  - 997-55-7 (N-acetylaspartate)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Antipsychotic Agents/*therapeutic use
MH  - Aspartic Acid/*analogs & derivatives/metabolism
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Prefrontal Cortex/*metabolism
MH  - Proton Magnetic Resonance Spectroscopy
MH  - Risperidone/*therapeutic use
MH  - Schizophrenia/diagnosis/*drug therapy/*metabolism
MH  - Young Adult
PMC - PMC4894446
EDAT- 2015/03/18 06:00
MHDA- 2016/02/26 06:00
PMCR- 2015/03/16
CRDT- 2015/03/18 06:00
PHST- 2014/12/13 00:00 [received]
PHST- 2015/02/19 00:00 [accepted]
PHST- 2015/03/18 06:00 [entrez]
PHST- 2015/03/18 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
PHST- 2015/03/16 00:00 [pmc-release]
AID - srep09109 [pii]
AID - 10.1038/srep09109 [doi]
PST - epublish
SO  - Sci Rep. 2015 Mar 16;5:9109. doi: 10.1038/srep09109.